US Pharmaceutical Tariffs Create Uneven Global Impact, India's Generics Offer Temporary Shield
The U.S. has imposed a 100% tariff on certain patented pharmaceutical imports, a move that escalates its trade policy and targets high-value drug manufacturing abroad. The order, based on a national security probe launched last year, cites concerns about foreign drug supply reliance. But its immediate impact on India is expected to be small. According to the Global Trade Research Initiative (GTRI), India's large export of low-cost generic medicines, making up over 90% of the U.S. drug market, currently shields it from the tariffs. These generics are expected to be exempt for about a year to prevent drug shortages and price increases.
US Strategy: Protectionism and Future Uncertainty
However, the tariffs reflect the U.S. administration's more assertive trade approach. Using national security justifications under Section 232, the tariffs aim to push drug companies to move manufacturing back to the U.S. and reduce reliance on foreign suppliers. This approach, supported by a recent Supreme Court decision on trade measures, shows a continued protectionist agenda that could affect trading partners, even those with trade deals. The possibility of tariffs expanding to generics or future investigations could create significant policy uncertainty for India's pharmaceutical sector, which exported $9.7 billion to the U.S. in 2025, accounting for 38% of its total exports.
Global Impact: Rivals and Market Trends
While India's generics are buffered, nations like Ireland, Switzerland, Germany, and others exporting patented, high-value drugs face more direct pressure. The EU exported about €92 billion in medicinal and pharmaceutical products to the U.S. in 2023, with the U.S. as its main market. The U.S. is the world's largest drug market, holding over half of global sales. Historically, U.S. tariff actions have significantly impacted Indian exports. Between May and September 2025, India's total exports to the U.S. dropped by 37.5%, with pharmaceuticals down 15.7% due to rising duties. This volatility previously caused sharp drops in Indian pharmaceutical stocks after tariff announcements. The global pharmaceutical sector also faces rising costs and supply chain issues, worsened by geopolitical tensions and protectionist policies.
Long-Term Risks for India's Pharma Exports
Despite the current exemption, the long-term outlook for India's pharmaceutical trade with the U.S. carries risks. A key concern is the evolving U.S. trade policy, which uses national security rules to reshape global supply chains. Ajay Srivastava, GTRI founder, notes that Indian firms making inputs for patented drugs or specialty medicines could still face tariffs. The 'generics exempt for now' status creates uncertainty, as reviews after a year could expand the tariffs. Tariffs are seen as an ineffective way to bring manufacturing back for low-margin generics, potentially leading to companies exiting the market and worsening drug shortages. Even with recent trade deals, the use of Section 232 and Section 301 shows a sustained focus on controlling supply chains, potentially sidelining export-dependent nations. India Ratings and Research (Ind-Ra) suggests that while U.S. revenue contribution has lessened, short-term disruptions are still possible due to contracts and pricing pressures.
The Future of Global Pharma Trade
The tariff announcements are viewed as a 'turning point' in global pharmaceutical trade, shifting towards a more geopolitically driven industrial policy. Analysts warn that while current measures may not immediately hurt India's generic exports, the growing protectionism remains a persistent challenge. This changing landscape requires Indian pharmaceutical companies to adapt and closely monitor future policy changes and trade term renegotiations. The U.S. focus on domestic production and supply chain resilience means international medicine trade could face greater scrutiny and potential restructuring.